Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active crohn's disease: A randomized, double-blind, placebo-controlled trial

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 3, 2006, Pages 325-334

  Schreiber, Stefan ^a   Feagan, Brian ^b   D'Haens, Geert ^c   Colombel, Jean Frederic ^d   Geboes, Karel ^e   Yurcov, Mikhail ^f   Isakov, Vasily ^g   Golovenko, Oleg ^h   Bernstein, Charles N ⁱ   Ludwig, Diether ^j   Winter, Trevor ^k   Meier, Ulrich ^l   Yong, Chan ^m   Steffgen, Jürgen ^l  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c IMELDA HOSPITAL   (Belgium)

^d University of Lille   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f City Proctological Center   (Russian Federation)

^g M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

^h State Center for Research in Coloproctology   (Russian Federation)

ⁱ Hohn Buhler Research Center   (Canada)

^j UNIVERSITY OF LÜBECK   (Germany)

^k UNIVERSITY OF CAPE TOWN   (South Africa)

^l BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^m BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; DORAMAPIMOD; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PLACEBO;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANUS FISTULA; ANUS PRURITUS; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOODY DIARRHEA; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; FEVER; FLATULENCE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; INFLUENZA; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROTOXICITY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SCORING SYSTEM; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; ADULT; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZOLES; TREATMENT OUTCOME;

EID: 33644756429     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2005.11.013     Document Type: Article

References (35)

1. S.H. Murch Local and systemic effects of macrophage cytokines in intestinal inflammation Nutrition 14 1998 780 783
2. W. Reinisch, C. Gasche, W. Tillinger Clinical relevance of serum interleukin-6 in Crohn's disease single point measurements, therapy monitoring, and prediction of clinical relapse Am J Gastroenterol 94 1999 2156 2164
3. H.C. Reinecker, M. Steffen, T. Witthoeft Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease Clin Exp Immunol 94 1993 174 181
4. S. Schreiber, S. Nikolaus, J. Hampe Tumor necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease Lancet 353 1999 459 461
5. S.H. Murch, C.P. Braegger, J.A. Walker-Smith Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease Gut 34 1993 1705 1709
6. F. Cominelli, C.C. Nast, A. Duchini Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis Gastroenterology 103 1992 65 71
7. R. Atreya, J. Mudter, S. Finotto Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation evidence in Crohn disease and experimental colitis in vivo Nat Med 6 2000 583 588
8. F. Powrie, M.W. Leach, S. Mauze Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells Immunity 1 1994 553 562
9. S.R. Targan, S.B. Hanauer, S.J.H. van Deventer A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease N Engl J Med 337 1997 1029 1035
10. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein Maintenance infliximab for Crohn's disease the ACCENT I randomised trial Lancet 359 2002 1541 1549
11. D.H. Present, P. Rutgeerts, S. Targan Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398 1405
12. S. Nikolaus, A. Raedler, T. Kuhbacker Mechanism in failure of infliximab for Crohn's disease Lancet 356 2000 1475 1479
13. W.J. Sandborn A review of biotechnology therapies for inflammatory bowel disease M. Mignon J.F. Colombel Recent advances in the pathophysiology and management of inflammatory bowel diseases and digestive endocrine tumors 1999 John Libbey Eurotext Paris 116 127
14. J.M. Kyriakis, J. Avruch Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation Physiol Rev 81 2001 807 869
15. G.H. Waetzig, D. Seegert, P. Rosenstiel p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease J Immunol 168 2002 5342 5351
16. J.C. Lee, J.T. Laydon, P.C. McDonnell A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature 372 1994 739 746
17. D.W. Hommes, M.P. Pepplenbosch, S.J.H. van Deventer Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets Gut 52 2003 144 151
18. C. Pargellis, L. Tong, L. Churchill Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nat Struct Biol 9 2002 268 272
19. J. Branger, B. van den Blink, S. Weijer Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia J Immunol 168 2002 4070 4077
20. Groupe d'etudes thérapeutiques des affections inflammatoires du tube digestif (getaid) Development and validation of an endoscopic index of the severity for Crohn's disease a prospective multicentre study Gut 30 1989 983 989
21. G.R. D'Haens, K. Geboes, M. Peeters Early lesions of Recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum Gastroenterology 114 1998 262 267
22. E.J. Irvine, B. Feagan, J. Rochon Quality of life a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease Gastroenterology 106 1994 287 296
23. D. Hommes, B. van den Blink, T. Plasse Inhibition of stress-activated MAP kinase induces clinical improvement in moderate to severe Crohn's disease Gastroenterology 122 2002 7 14
24. S. Koprak, M.J. Staruch, F.J. Dumont A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated T cells dependence on CD28 signaling and preferential inhibition of IL-10 production Cell Immunol 192 1999 87 95
25. R. Kuhn, J. Lohler, D. Rennick Interleukin-10-deficient mice develop chronic enterocolitis Cell 75 1993 263 274
26. S. Schreiber, R.N. Fedorak, O.H. Nielsen Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease Gastroenterology 119 2000 4161 4172
27. J.M.H. van den Brande, H. Braat, G.R. van den Brink Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease Gastroenterology 124 2003 1774 1785
28. A.D. Di Sabatino, R. Ciccocioppo, B. Clinque Defective mucosal T cell death is sustainably reverted by Infliximab in a caspase dependent pathway in Crohn's disease Gut 53 2004 70 77
29. W.J. Sandborn, S.B. Hanauer, S. Katz Etanercept for active Crohn's disease a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
30. P. Rosenstiel, J. Agnolt, J. Kelsen Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease Gut 54 2005 314 315
31. T. ten Hove, B. van den Blink, I. Pronk Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis Gut 50 2002 507 512
32. G. Malamut, C. Cabane, B. Derijard Decreased activity of mitogen-activated protein kinases (MAPK) p38 and JNK in patients with inflammatory bowel diseases without therapeutic effect of p38 inhibitor in experimental model of colitis Gut 51 Suppl III 2002 A37
33. A.L. Buchman, S. Katz, C. Barish Semapimod treatment of Crohn's disease Gastroenterology 126 Suppl 2 2004 A464 A465
34. C. Su, G.R. Lichtenstein, K. Krok A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease Gastroenterology 126 2004 1257 1269
35. M. Weisman, D. Furst, M. Schiff A double-blind placebo-controlled trial of VX-745, an oral P38 mitogen activated protein kinase (MAPK) inhibitor, in patients with rheumatoid arthritis (RA) Ann Rheum Dis 61 2002 166